AstraZeneca publishes interim vaccine data in Lancet, reveals 10 hospitalizations, 1 death in pivotal control arms

Kyle Blankenship

After reading out interim results in mid-November, AstraZeneca has been hot on the heels of Pfizer and Moderna in getting its adenovirus-based vaccine past regulators’ …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AstraZeneca publishes interim vaccine data in Lancet, reveals 10 hospitalizations, 1 death in pivotal control arms

Kyle Blankenship

Sign up to read this article for free.

Safety concerns and trial holds for pediatric RSV vaccines prompt caution from FDA adcomm

Inside Isomorphic Labs: Demis Hassabis’ lab-free vision for biotech’s AI future

Pfizer shares positive Phase 3 results in breast cancer subset

'Serious liver injury' cases lead FDA to call for monitoring of Ocaliva patients

Editas to cut 65% of workforce, officially stops work on ex vivo sickle cell therapy

The key to faster, more impactful research? Put patients in the driver’s seat

As­traZeneca pub­lish­es in­ter­im vac­cine da­ta in Lancet, re­veals 10 hos­pi­tal­iza­tions, 1 death in piv­otal con­trol arms

Kyle Blankenship

Sign up to read this article for free.

Safe­ty con­cerns and tri­al holds for pe­di­atric RSV vac­cines prompt cau­tion from FDA ad­comm

In­side Iso­mor­phic Labs: Demis Has­s­abis’ lab-free vi­sion for biotech’s AI fu­ture

Pfiz­er shares pos­i­tive Phase 3 re­sults in breast can­cer sub­set

'Se­ri­ous liv­er in­jury' cas­es lead FDA to call for mon­i­tor­ing of Ocali­va pa­tients

Ed­i­tas to cut 65% of work­force, of­fi­cial­ly stops work on ex vi­vo sick­le cell ther­a­py

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

AstraZeneca publishes interim vaccine data in Lancet, reveals 10 hospitalizations, 1 death in pivotal control arms

Safety concerns and trial holds for pediatric RSV vaccines prompt caution from FDA adcomm

Inside Isomorphic Labs: Demis Hassabis’ lab-free vision for biotech’s AI future

Pfizer shares positive Phase 3 results in breast cancer subset

'Serious liver injury' cases lead FDA to call for monitoring of Ocaliva patients

Editas to cut 65% of workforce, officially stops work on ex vivo sickle cell therapy

The key to faster, more impactful research? Put patients in the driver’s seat